Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.

Khor, Sara

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. [electronic resource] - BMC cancer Aug 2014 - 586 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1471-2407

10.1186/1471-2407-14-586 doi


Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived--economics
Antineoplastic Agents--economics
Antineoplastic Combined Chemotherapy Protocols--economics
Child
Child, Preschool
Cost-Benefit Analysis
Female
Humans
Infant
Lymphoma, Large B-Cell, Diffuse--drug therapy
Male
Middle Aged
Models, Economic
Ontario
Rituximab
Survival Rate
Young Adult